Larson Financial Group’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$401K Sell
7,292
-198
-3% -$8.1K 0.01% 620
2026
Q1
$249K Buy
7,490
+326
+5% +$9.71K 0.01% 653
2025
Q4
$214K Buy
7,164
+122
+2% +$3.98K 0.01% 683
2025
Q3
$254K Buy
7,042
+231
+3% +$7.61K 0.01% 633
2025
Q2
$245K Buy
6,811
+6,240
+1,093% +$232K 0.01% 621
2025
Q1
$22.5K Buy
571
+227
+66% +$7.64K ﹤0.01% 1312
2024
Q4
$10.4K Buy
+344
New +$9.87K ﹤0.01% 1472

Other funds holding TGTX

Larson Financial Group's TGTX Position: Q2 2026 in Review

Larson Financial Group reduced its TG Therapeutics (TGTX) stake by 2.6% in Q2 2026, selling an estimated $8.1K and leaving 7,292 shares worth $401K. The position accounts for 0.01% of the portfolio, ranked #620.

Larson Financial Group first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Larson Financial Group held 7,292 shares of TG Therapeutics worth $401K as of Q2 2026.
  • Larson Financial Group sold 198 TG Therapeutics shares in Q2 2026, an estimated $8.1K.
  • TG Therapeutics made up 0.01% of Larson Financial Group's portfolio in Q2 2026, its #620 holding.
  • Larson Financial Group first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.